Hashimoto Thyroiditis Global Clinical Trials Review, H2, 2017

2017-08-31
Price :
Published : Aug-2017
No. of Pages : 47

Hashimoto Thyroiditis Global Clinical Trials Review, H2, 2017

Summary

GlobalData’s clinical trial report, “Hashimoto Thyroiditis Global Clinical Trials Review, H2, 2017” provides an overview of Hashimoto Thyroiditis clinical trials scenario. This report provides top line data relating to the clinical trials on Hashimoto Thyroiditis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Heidelberg Pharma AG (WL6) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Heidelberg Pharma AG(Heidelberg Pharma) formerly known as Wilex AG is a biopharmaceutical company with a focus on cancer. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. It develops products based on and small molecules and antibodies, which are offered for out-licensing. Wilex's pipeline products are focused at treating multiple myeloma, prostate cancer, hematological cancers, metastatic pancreatic cancers, leukemia, non- metastatic ccRCC, kidney cancers and solid tumors. Heidelberg Pharma GmbH (Heidelberg), Wilex's subsidiary provides preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Heidelberg focuses on the development of a proprietary ADC technology. ......
$250

Taiho Pharmaceutical Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group focuses on the development, production and marketing of pharmaceutical products in the fields of cancer, allergy, immunology, urology and others. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor antagonists, antibiotics and medical devices; and consumer health products such as vitamin tonic, herbal digestive medicine, topical analgesics, antifungal cream, herbal medicine powder, and others. Taiho has production facilities in Tokushima, Saitama, Okayama, Kitajima and Inuyama. It operates through its subsidiaries in Japan, China, Singapore, the UK and the US. Taiho is headquartered in Tokyo, Japan. Taiho Pharmaceutical Co Ltd - Pharmaceuticals & Healt......
$250

Evotec AG (EVT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides services such as integrated services, assay development and screening, reagent production services, ADMET, cellular target profiling, vitro pharmacology services and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and also has development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Manchester, the UK; Gottingen and M......
$250

Weifa ASA (WEIFA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering products for pain relief; treatment of cough and colds; dermatology; Nutraceuticals; dietary supplements; and wound treatment among others. Its research and development activities focus on prescription drug products, OTC products and nutraceuticals. It offers products to consumers, customers and professional partners. The company has operational presence in Denmark, Iceland, Sweden and Finland. Weifa is headquartered in Oslo, Norway. Weifa ASA (WEIFA) - Pharmaceuticals & Healthcare - Deals and ......
$250

OpGen Inc (OPGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company's clinical laboratory services include high resolution microbial sequence analysis, swift detection and analysis of antibiotic resistance, and detection of pathogens in blood cultures. It is also developing Acuitas Lighthouse, an exhaustive database of various types of pathogens for providing rapid diagnostics, and healthcare management information. OpGen offers its surveillance products and customized screening services to healthcare providers to protect the hospital biome and optimize patient care. The company sells its products in the US and abroad. OpGen is headquartered in......
$250

Navidea Biopharmaceuticals Inc (NAVB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Navidea Biopharmaceuticals Inc (Navidea) is a precision medicine company that focuses on the development and commercialization of radiopharmaceutical agents and precision diagnostics. Its key product, Lymphoseek (technetium Tc 99m tilmanocept) injection, is a radiopharmaceutical agent used in intra-operative lymphatic mapping (ILM), external lymph node imaging (lymphoscintigraphy) and sentinel lymph node biopsy. The company's products in pipeline includes lifecycle management of Lymphoseek; and NAV4694, a fluorine-18 PET (positron emission tomography) imaging agent, is being developed for the diagnosis of cognitive impairment and dementia, including Alzhemier's disease. Navidea by utilizing its Manocept platform develops multiple precision-targeted products to identify pathways of......
$250

MediciNova Inc (MNOV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary MediciNova Inc (MediciNova) is a biopharmaceutical company, which focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurology, respiratory, and liver diseases. MediciNova's developmental pipeline includes core programs such as MN-001, for the treatment of nonalcoholic steatohepatitis; MN-166, for neurological disorders; and MN-221, for respiratory diseases. The company's non-core programs include MN-001 being developed for two indications, namely, bronchial asthma and interstitial cystitis; MN-029 for the treatment of solid tumors; and MN-221 for the treatment of preterm labor. It has partnerships with various companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd and Meiji Seika ......
$250

H. Lundbeck AS (LUN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary H. Lundbeck A/S (Lundbeck), a subsidiary of The Lundbeck Foundation carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system (CNS) related diseases including psychiatric and neurological disorders. Its products are used in the treatment of diseases such as Alzheimer's disease, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington's disease among others. The company has production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck's products are sold primarily to pharmaceutical distributors, pharmacies and hospitals. It sells its products in Europe, USA and other countries. Lundbeck is headqua......
$250

Geron Corp (GERN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. IMbark is a Phase II, randomized, single-blind and multi-center study for patients with high risk myelofibrosis (MF) whose disease is relapsed after or refractory to JAK inhibitor treatment; and IMerge is a Phase 2/3, multi-center study of imetelstat in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS). Geron also has collaboration and royalty agreements with companies in oncology, diagnostics, biologics and research tools production domains. Ger......
$250

Linde AG (LIN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Linde AG (Linde) is a provider of industrial gases and engineering services. The company specializes in the planning, procurement, construction and operation of gas production and processing plants. Linde offers a wide range of compressed and liquefied gases, and chemicals, and offers facilities and equipment for gas applications. The company provides gases, therapies, consultation and supporting services for respiratory medicine. It also offers engineering services to petrochemical and chemical industries. . The company serves various sectors including energy, steel, chemical, environmental protection, welding, food processing, glass, electronics and others. It has operations in Europe, North America, AsiaPacific, South America and Africa. Linde is headquartered in Munich, Germ......
$250